Skip to main content

Rossari Biotech debuts at Rs 670 with 58% premium over IPO price

The listing premium was much higher than the grey market premium (of around Rs 160-180 per share) as well as analysts' expectations of Rs 130-175 per share.

The Mumbai-based specialty chemical maker Rossari Biotech started the first trading day with a whopping 57.65 percent premium over its IPO price on July 23.

The stock opened at Rs 670 on the BSE, up by Rs 245 over the issue price of Rs 425 per share, while on the National Stock Exchange, it debuted at Rs 669.25, a 57.47 percent premium over IPO price.

It was much higher than the grey market premium (of around Rs 160-180 per share) as well as analysts' expectations of Rs 130-175 per share.

At 10:01 hours IST, the stock was trading at Rs 675 on the BSE, up by Rs 250 or 58.82 percent over issue price with a volume of 3.83 lakh shares.

The exchange has fixed a 20 percent upper and lower circuit limit at Rs 804 and Rs 536 respectively, over its opening price of Rs 670.

On the National Stock Exchange, the share price traded at Rs 676.75, up by Rs 251.75 or 59.24 percent over IPO price, with volumes of 40,88,564 equity shares.

The Rs 496-crore initial public offering of Rossari Biotech had seen a hefty subscription of 79.37 times during July 13-15.

The public issue consisted a fresh issue of Rs 50 crore and offer for sale of 1.05 crore shares by promoters Edward Menezes and Sunil Chari.

Promoters and promoter group's shareholding in the company reduced to 72.69 percent post issue, from 95.06 percent earlier.


The company will utilise fresh issue proceeds for repayment/prepayment of certain indebtedness (including accrued interest) and funding working capital requirements, while it will not receive any funds from offer for sale.

Rossari manufactures majority of its products in-house from its Silvassa manufacturing facility which has an installed capacity of 1,20,000 MTPA. Now the company is currently setting up another manufacturing facility at Dahej in Gujarat with a proposed installed capacity of 1,32,500 MTPA which will enjoy proximity to the deep water, multi-cargo port of Dahej. The proposed state-of-the-art facility will be fully operational by March 2021.

Manufacturing of disinfectants & sanitizers as part of the Home, Personal Care & Performance Chemicals led the company's products to get categorized under essential goods, thus its manufacturing facility at Silvassa was not shut down during COVID-19 lockdown period.

Previously, company's business was much dependent on the textile space (nearly 71 percent revenue came from textile in FY18 which reduced to 44 percent in FY20), but steadily company has brought down the revenue share and simultaneously the revenue share of Home & Personal care division has increased and current it accounts nearly 47 percent of FY20 revenue, which turns a big positive for Rossari Biotech, said Ashika Stock Broking.

Source - Moneycontrol

 


Labels:

Comments

Post a Comment

Popular posts from this blog

Reliance Jio Q3 results: Profit grows to Rs 3,489 crore; ARPU rises to Rs 151

  The average revenue per user (ARPU) during the quarter came at Rs 151 per subscriber per month as against Rs 145 per subscriber per month in the September quarter. Reliance Jio, the telecommunications arm of Jio Platforms, on January 22 posted a net profit of Rs 3,489 crore for the quarter ended December 31, 2020. The profit was higher than the street expectations as analysts in a CNBC-TV18 poll had estimated the number at Rs 3,200 crore. Jio's net profit grew 15.5 percent QoQ as in the September quarter of FY21, its profit was Rs 3,020 crore. The average revenue per user (ARPU) during the quarter came at Rs 151 per subscriber per month as against Rs 145 per subscriber per month in the September quarter. A CNBC-TV18 poll had estimated ARPU at Rs 148.2. Revenue, including access revenues for the quarter, was Rs 22,858 crore ($3.1 billion), up 5.3 percent QoQ. A CNBC-TV18 poll had estimated revenue to the tune of Rs 18,165 crore. EBITDA for the quarter stood at Rs 8,483 crore ...
Post a Comment
Read more

Futures Trade | A bullish breakout of a flag pattern in HDFC

HDFC is moving in an uptrend with a minor corrective decline. The range is classified as a flag and a breakout of falling minor trendline confirms a possible upside. HDFC is moving in an uptrend with a minor corrective decline from Nov 20 highs. The decline is on lower, contracting volumes and suggests a correction within an ongoing trend. The range-bound action can also be classified as a flag as it is on coming off a sharp rally. A breakout of falling minor trendline confirms a possible upside. Buy around Rs 2300-2310. Keep a stop below Rs 2250 and hold for a target of Rs 2400 and above that to Rs 2450.
Post a Comment
Read more

Taking Stock | Profit-booking pulls Nifty below 14,450; Sensex drops 549 points

  All the sectoral indices ended in the red with IT and PSU bank indices falling 2 percent each. The market remained under pressure on January 15 on the back of profit-booking across sectors amid weak global cues. At close, the Sensex was down 549.49 points or 1.11% at 49,034.67, and Nifty was down 161.90 points or 1.11% at 14,433.70. "The market witnessed profit-booking and following global trends. Nifty continues to resist 14,600 and has taken a dip towards 14,360. If the market closes below 14,380 levels, we might see a correction till the levels of 14,180-14,200. Momentum indicators like RSI, MACD are indicating a small correction in the markets," said Ashis Biswas, Head of Research at CapitalVia Global Research. All the sectoral indices ended in the red with IT and PSU bank falling 2 percent each. Broader markets performed in line with the main indices with BSE Midcap and Smallcap indices falling 1 percent each. Tech Mahindra, GAIL, HCL Tech, Wipro and ONGC...
Post a Comment
Read more